ZB
DXCM icon

Zions Bancorporation’s DexCom DXCM Stock Holding History

Zions Bancorporation’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$3.89K Sell
50
-84
-63% -$6.22K ﹤0.01% 728
2024
Q3 		$8.98K Sell
134
-76
-36% -$6.24K ﹤0.01% 641
2024
Q2 		$23.8K Sell
210
-78
-27% -$9.86K ﹤0.01% 518
2024
Q1 		$39.9K Sell
288
-1,813
-86% -$228K ﹤0.01% 454
2023
Q4 		$261K Sell
2,101
-20,347
-91% -$2.08M 0.02% 296
2023
Q3 		$2.09M Buy
22,448
+801
+4% +$90.3K 0.18% 89
2023
Q2 		$2.78M Sell
21,647
-1,639
-7% -$198K 0.24% 77
2023
Q1 		$2.71M Buy
23,286
+2,587
+12% +$290K 0.23% 75
2022
Q4 		$2.34M Buy
20,699
+2,295
+12% +$252K 0.19% 82
2022
Q3 		$1.48M Buy
18,404
+908
+5% +$76.9K 0.16% 102
2022
Q2 		$1.3M Buy
17,496
+6,760
+63% +$617K 0.13% 117
2022
Q1 		$1.37M Buy
10,736
+4,100
+62% +$448K 0.12% 113
2021
Q4 		$891K Buy
6,636
+936
+16% +$134K 0.08% 146
2021
Q3 		$779K Buy
5,700
+908
+19% +$115K 0.08% 140
2021
Q2 		$512K Buy
4,792
+4,288
+851% +$412K 0.05% 172
2021
Q1 		$45K Sell
504
-28
-5% -$2.63K 0.01% 437
2020
Q4 		$49K Buy
532
+4
+0.8% +$357 0.01% 396
2020
Q3 		$54K Buy
528
+276
+110% +$28.8K 0.01% 364
2020
Q2 		$26K Buy
252
+100
+66% +$8.95K ﹤0.01% 441
2020
Q1 		$10K Buy
152
+40
+36% +$2.49K ﹤0.01% 583
2019
Q4 		$6K Buy
112
+48
+75% +$2.28K ﹤0.01% 780
2019
Q3 		$2K Sell
64
-28
-30% -$1.09K ﹤0.01% 866
2019
Q2 		$3K Hold
92
– – ﹤0.01% 773
2019
Q1 		$3K Buy
+92
New +$3.23K ﹤0.01% 809
2018
Q2 		– Sell
-152
Closed -$3K – 510
2018
Q1 		$3K Buy
+152
New +$2.25K ﹤0.01% 472
2017
Q4 		– Sell
-13,076
Closed -$160K – 713
2017
Q3 		$160K Buy
13,076
+13,040
+36,222% +$231K 0.02% 309
2017
Q2 		$1K Buy
+36
New +$665 ﹤0.01% 633
2016
Q3 		– Sell
-4
Closed – – 844
2016
Q2 		$0 Buy
+4
New +$68 ﹤0.01% 847

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Zions Bancorporation's DXCM Position: Q4 2024 in Review

Zions Bancorporation reduced its DexCom (DXCM) stake by 63% in Q4 2024, selling an estimated $6.22K and leaving 50 shares worth $3.89K. The position accounts for ﹤0.01% of the portfolio, ranked #728.

Zions Bancorporation first reported a position in DXCM in Q2 2016 and has held it in 28 quarters since. The position peaked at $2.78M in Q2 2023. 951 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

  • Zions Bancorporation held 50 shares of DexCom worth $3.89K as of Q4 2024.
  • Zions Bancorporation sold 84 DexCom shares in Q4 2024, an estimated $6.22K.
  • DexCom made up ﹤0.01% of Zions Bancorporation's portfolio in Q4 2024, its #728 holding.
  • Zions Bancorporation first reported a position in DexCom in Q2 2016 and has held it in 28 quarters since.
  • Zions Bancorporation's DexCom position peaked at $2.78M in Q2 2023.
  • 951 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.